

Curriculum Vitae

Name: Steven E. Shoelson
Degree: Ph.D., M.D.
Affiliation: Joslin Diabetes Center
Harvard Medical School
Position Title: Professor of Medicine

Education/Training

1976 B.S. Florida State University (Chemistry)
1984 Ph.D. University of Chicago, Organic Chemistry
1985 M.D. University of Chicago, Pritzker School of Medicine
1985-88 Residency, Internal Medicine, Brigham and Women's Hospital, Boston

Positions and Scientific Appointments

1988-1990 Instructor in Medicine, Harvard Medical School
1990-2016 Faculty, MD-PhD Program, Harvard Medical School.
1991-1995 Assistant Professor of Medicine, Harvard Medical School.
1995-2003 Associate Professor of Medicine, Harvard Medical School.
1999-2019 Member, Dept of Biological Chemistry and Molecular Pharmacology, Harvard Medical School.
2001- Faculty, Biophysics Graduate Program, Committee on Higher Degrees in Biophysics, Harvard University.
2002- Helen and Morton Adler Chair, Joslin Diabetes Center.
2002-10 Head, Section on Cellular and Molecular Physiology, Joslin Diabetes Center
2002-2019 Member, Biological and Biomedical Sciences Program, Harvard Med School
2003- Professor of Medicine, Harvard Medical School.
2003- Associate Director of the Research Division, Joslin Diabetes Center.
2008-2021 Associate Director, Joslin-NIDDK Diabetes Research Center (DRC).
2008-2021 Director, Joslin DRC Pilot & Feasibility Grant Program.
2010-2021 Head, Section on Pathophysiology and Molecular Pharmacology.

Honors

1995 Burroughs-Wellcome Fund Scholar Award in Experimental Therapeutics.
1996 Juvenile Diabetes Foundation/Boehringer Mannheim Diabetes Care Award.
2005 MERIT Award from NIH-NIDDK.
2006 Kroc Visiting Professor in Diabetes, University of Alabama.
2008 The Caledonian Prize of the Royal Society of Edinburgh.
2010 Kroc Lectureship in Diabetes and Obesity, Univ of Washington, Seattle.
2012 Donald F. Steiner Award, Outstanding Achievement in Diabetes Research.

Selected Publication

Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.W., Karin, M., and Shoelson, S.E. (2001). Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of *Ikk β* . *Science* 293, 1673-1677.

Cai D, Yuan M, Frantz JD, Melendez PA, Hansen L, Lee J, Shoelson SE (2005) Local and systemic insulin resistance due to hepatic activation of IKK β and NF- κ B. *Nature Medicine* 11, 183-190.

Cai D, Frantz JD, Tawa NE, Melendez PA, Oh B-C, Lidov HGW, Hasselgren P-O, Frontera WR, Lee J, Glass DJ, Shoelson SE. (2004) IKK β /NF- κ B activation causes severe muscle wasting in mice. *Cell* 119, 285-298.

Donath MY and Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. *Nat Rev Immunol.* 11, 98-107.

Goldfine AB, Fonseca V, Jablonski KA, Chen Y-DI, Tipton L, Staten MA and Shoelson SE. (2013) One Year Randomized, Controlled Trial of Salicylate (Salsalate) in Patients with Type 2 Diabetes. *Ann. Intern. Med.* 159, 1-12.

Lee BC, Kim MS, Pae M, Yamamoto Y, Eberlé D, Shimada T, Kamei N, Park H-S, Sasorith S, Woo JR, You J, Mosher W, Brady HJM, Shoelson SE & Lee J (2016) Adipose natural killer cells regulate adipose tissue macrophages to promote insulin resistance in obesity. *Cell Metabolism* 12, 685-698.

Kim OH, Kang GH, Hur J, Lee J, Jung Y, Hong IS, Lee H, Seo SY, Lee DH, Lee CS, Lee IK, Bonner-Weir S, Lee J, Park YJ, Kim H, Shoelson SE, Oh BC (2022) Externalized phosphatidylinositides on apoptotic cells are eat-me signals recognized by CD14. *Cell Death Differ* 29, 1423-1432.